HC Wainwright Brokers Increase Earnings Estimates for Insmed

Insmed, Inc. (NASDAQ:INSM) – Equities research analysts at HC Wainwright raised their Q3 2026 earnings per share (EPS) estimates for shares of Insmed in a note issued to investors on Monday, August 10th. HC Wainwright analyst A. Fein now anticipates that the biopharmaceutical company will post earnings per share of ($0.31) for the quarter, up from their previous forecast of ($0.82). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Insmed’s current full-year earnings is ($2.00) per share. HC Wainwright also issued estimates for Insmed’s Q4 2026 earnings at ($0.49) EPS, FY2027 earnings at $1.62 EPS, FY2028 earnings at $3.38 EPS and FY2030 earnings at $10.92 EPS.

Several other equities research analysts have also recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Insmed in a research report on Friday, July 17th. BMO Capital Markets assumed coverage on shares of Insmed in a report on Monday, July 20th. They issued an “outperform” rating and a $192.00 target price on the stock. Roth Capital reaffirmed a “buy” rating on shares of Insmed in a research report on Monday, June 8th. UBS Group reiterated a “buy” rating and set a $172.00 price target on shares of Insmed in a report on Friday. Finally, Evercore reissued an “outperform” rating and issued a $170.00 price objective on shares of Insmed in a research report on Friday. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $205.52.

Insmed Stock Down 1.6%

Shares of NASDAQ INSM opened at $132.57 on Wednesday. The company has a market capitalization of $28.95 billion, a P/E ratio of -32.26 and a beta of 0.81. Insmed has a 52-week low of $90.39 and a 52-week high of $212.75. The company has a debt-to-equity ratio of 0.74, a quick ratio of 3.40 and a current ratio of 3.72. The company’s 50 day moving average price is $106.29 and its 200-day moving average price is $128.64.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.61. Insmed had a negative return on equity of 123.94% and a negative net margin of 76.94%.The firm had revenue of $425.49 million for the quarter, compared to the consensus estimate of $395.50 million. During the same period in the previous year, the business earned ($1.70) EPS. The business’s quarterly revenue was up 296.1% compared to the same quarter last year.

Institutional Investors Weigh In On Insmed

Several institutional investors have recently bought and sold shares of INSM. Reflection Asset Management bought a new position in Insmed during the 4th quarter valued at $30,000. CIBC Private Wealth Group LLC grew its stake in shares of Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 53 shares in the last quarter. Raiffeisen Bank International AG purchased a new stake in shares of Insmed in the fourth quarter valued at about $32,000. Larson Financial Group LLC raised its holdings in shares of Insmed by 137.0% in the fourth quarter. Larson Financial Group LLC now owns 256 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 148 shares during the last quarter. Finally, Towarzystwo Funduszy Inwestycyjnych PZU SA purchased a new stake in shares of Insmed in the fourth quarter valued at about $49,000.

Insider Activity at Insmed

In related news, CEO William Lewis sold 10,699 shares of the business’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $117.40, for a total value of $1,256,062.60. Following the completion of the sale, the chief executive officer directly owned 259,058 shares of the company’s stock, valued at $30,413,409.20. The trade was a 3.97% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Michael Alexander Smith sold 1,806 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $95.82, for a total value of $173,050.92. Following the sale, the insider owned 37,648 shares of the company’s stock, valued at approximately $3,607,431.36. This represents a 4.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 54,590 shares of company stock valued at $5,793,738. 2.10% of the stock is currently owned by company insiders.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.